How to determine resistance to the targeted drug acotinib?

The process of determining resistance to the targeted drug acotinib (Acalabrutinib) usually requires a combination of clinical manifestations, disease progression, molecular biology testing and other factors. The following are common methods and indicators for determining acotinib resistance:

1.Clinical manifestations: If a patient develops clinical manifestations of disease progression or deterioration during treatment with acotinib, such as lymphadenopathy, anemia, persistent fever, weight loss, etc., it may indicate that the patient is resistant to acotinib.

2.Imaging examinations: Regular imaging examinations (such as CTscan, MRI, etc.) to observe the size, number and distribution of disease lesions. New growth or enlargement of the lesions may indicate resistance to acotinib.

3.Hematological indicators: Regularly monitor the patient's hematological indicators, such as white blood cell count, platelet count, etc. Abnormal changes such as increased white blood cell count and decreased platelet count may be one of the manifestations of acotinib resistance.

4.Molecular biology testing: Detect specific gene mutations or expression level changes in tumor tissue or blood samples through molecular biology techniques. For example, BTK gene mutations or variations in other signaling pathway-related genes can be detected to evaluate whether acotinib can still effectively inhibit the growth and proliferation of tumor cells.

5.Duration of treatment response: observe the duration of the patient’s response to acotinib treatment. If the patient's condition progresses or relapses within a short period of time, it may indicate that the patient has developed resistance to acotinib.

To sum up, the process of determining resistance to the targeted drug acotinib is a comprehensive assessment process, which requires a combination of clinical manifestations, imaging examinations, hematological indicators, molecular biology testing and other methods and indicators for judgment. Once it is confirmed that a patient is resistant to acotinib, doctors may need to adjust the treatment plan and consider other treatment options, such as dressing changes, combination therapy, or clinical trials, to achieve better therapeutic effects.